

MEDTRONIC PLC
WORLD WIDE REVENUE
(Unaudited)

(in millions)	SECOND QUARTER AS REPORTED			SECOND QUARTER CONSTANT CURRENCY ADJUSTED				SECOND QUARTER YTD AS REPORTED			SECOND QUARTER YTD CONSTANT CURRENCY ADJUSTED			
	FY17 Q2	FY16 Q2	Reported Growth	FY17 Q2	FY16 Q2	Currency Impact on Revenue	Constant Currency Growth (2)	FY17 Q2 YTD	FY16 Q2 YTD	Reported Growth (1)	FY17 Q2 YTD	FY16 Q2 YTD	Currency Impact on Revenue	Constant Currency Growth (1)(2)
Cardiac & Vascular Group	\$ 2,584	\$ 2,488	4%	\$ 2,584	\$ 2,488	\$ 12	3%	\$ 5,102	\$ 5,060	1%	\$ 5,102	\$ 5,060	\$ 5	1%
Cardiac Rhythm & Heart Failure	1,400	1,324	6	1,400	1,324	8	5	2,734	2,694	1	2,734	2,694	9	1
Coronary & Structural Heart	753	754	—	753	754	1	—	1,515	1,542	(2)	1,515	1,542	(7)	(1)
Aortic & Peripheral Vascular (3)	431	410	5	431	410	3	4	853	824	4	853	824	3	3
Minimally Invasive Therapies Group	2,473	2,356	5	2,473	2,356	29	4	4,897	4,812	2	4,897	4,812	32	1
Surgical Solutions	1,361	1,291	5	1,361	1,291	14	4	2,709	2,643	2	2,709	2,643	12	2
Patient Monitoring & Recovery	1,112	1,065	4	1,112	1,065	15	3	2,188	2,169	1	2,188	2,169	20	—
Restorative Therapies Group (3)	1,826	1,764	4	1,826	1,764	10	3	3,598	3,566	1	3,598	3,566	10	1
Spine	663	649	2	663	649	5	1	1,308	1,334	(2)	1,308	1,334	6	(2)
Brain Therapies	506	475	7	506	475	3	6	995	937	6	995	937	2	6
Specialty Therapies	369	347	6	369	347	1	6	725	693	5	725	693	1	4
Pain Therapies	288	293	(2)	288	293	1	(2)	570	602	(5)	570	602	1	(5)
Diabetes Group	462	450	3	462	450	(1)	3	914	894	2	914	894	(4)	3
TOTAL	\$ 7,345	\$ 7,058	4%	\$ 7,345	\$ 7,058	\$ 50	3%	\$ 14,511	\$ 14,332	1%	\$ 14,511	\$ 14,332	\$ 43	1%

See description of non-GAAP financial measures at the end of the earnings press release.

(1) Fiscal year 2016 was a 53-week year, with the extra week included in the first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates that the extra week impact on first quarter revenue was approximately \$450 million.

(2) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior year periods using average exchange rates in effect during the applicable prior year period.

(3) In fiscal year 2017, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from certain product lines in Restorative Therapies Group to Cardiac & Vascular Group's Aortic & Peripheral Vascular division. As a result, fiscal year 2016 results have been recast to adjust for this realignment.

MEDTRONIC PLC
U.S. REVENUE⁽³⁾
(Unaudited)

(in millions)	SECOND QUARTER AS REPORTED			SECOND QUARTER YTD AS REPORTED		
	FY17 Q2	FY16 Q2	Reported Growth	FY17 Q2 YTD	FY16 Q2 YTD	Reported Growth (1)
Cardiac & Vascular Group	\$ 1,353	\$ 1,340	1%	\$ 2,650	\$ 2,696	(2)%
Cardiac Rhythm & Heart Failure	805	768	5	1,563	1,554	1
Coronary & Structural Heart	289	323	(11)	583	651	(10)
Aortic & Peripheral Vascular (2)	259	249	4	504	491	3
Minimally Invasive Therapies Group	1,266	1,263	—	2,501	2,555	(2)%
Surgical Solutions	586	573	2	1,163	1,160	—
Patient Monitoring & Recovery	680	690	(1)	1,338	1,395	(4)
Restorative Therapies Group (2)	1,261	1,215	4	2,468	2,435	1
Spine	469	454	3	921	916	1
Brain Therapies	293	272	8	571	536	7
Specialty Therapies	285	267	4	559	531	5
Pain Therapies	214	222	(4)	417	452	(8)
Diabetes Group	272	280	(3)	535	554	(3)
TOTAL	\$ 4,152	\$ 4,098	1%	\$ 8,154	\$ 8,240	(1)%

(1) Fiscal year 2016 was a 53-week year, with the extra week included in the first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates that the extra week impact on first quarter revenue was approximately \$450 million.

(2) In fiscal year 2017, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from certain product lines in Restorative Therapies Group to Cardiac & Vascular Group's Aortic & Peripheral Vascular division. As a result, fiscal year 2016 results have been recast to adjust for this realignment.

(3) U.S. includes the United States and U.S. territories.

MEDTRONIC PLC
WORLD WIDE REVENUE: GEOGRAPHIC⁽⁴⁾
(Unaudited)

(in millions)	SECOND QUARTER AS REPORTED			SECOND QUARTER CONSTANT CURRENCY ADJUSTED				SECOND QUARTER YTD AS REPORTED			SECOND QUARTER YTD CONSTANT CURRENCY ADJUSTED			
	FY17 Q2	FY16 Q2	Reported Growth	FY17 Q2	FY16 Q2	Currency Impact on Revenue	Constant Currency Growth (2)	FY17 Q2 YTD	FY16 Q2 YTD	Reported Growth (1)	FY17 Q2 YTD	FY16 Q2 YTD	Currency Impact on Revenue	Constant Currency Growth (1)(2)
U.S.	\$ 1,353	\$ 1,340	1%	\$ 1,353	\$ 1,340	\$ —	1%	\$ 2,650	\$ 2,696	(2)%	\$ 2,650	\$ 2,696	\$ —	(2)%
Non-U.S. Developed	823	772	7	823	772	16	5	1,652	1,603	3	1,652	\$ 1,603	31	1
Emerging Markets	408	376	9	408	376	(4)	10	800	761	5	800	\$ 761	(26)	9
Cardiac & Vascular Group (3)	2,584	2,488	4	2,584	2,488	12	3	5,102	5,060	1	5,102	5,060	5	1
U.S.	1,266	1,263	—	1,266	1,263	—	—	2,501	2,555	(2)	2,501	2,555	—	(2)
Non-U.S. Developed	853	777	10	853	777	34	5	1,716	1,618	6	1,716	1,618	56	3
Emerging Markets	354	316	12	354	316	(5)	14	680	639	6	680	639	(25)	10
Minimally Invasive Therapies Group	2,473	2,356	5	2,473	2,356	29	4	4,897	4,812	2	4,897	4,812	31	1
U.S.	1,261	1,215	4	1,261	1,215	—	4	2,468	2,435	1	2,468	2,435	—	1
Non-U.S. Developed	383	368	4	383	368	13	1	767	754	2	767	754	22	(1)
Emerging Markets	182	181	1	182	181	(3)	2	363	377	(4)	363	377	(12)	(1)
Restorative Therapies Group (3)	1,826	1,764	4	1,826	1,764	10	3	3,598	3,566	1	3,598	3,566	10	1
U.S.	272	280	(3)	272	280	—	(3)	535	554	(3)	535	554	—	(3)
Non-U.S. Developed	150	135	11	150	135	(1)	12	305	274	11	305	274	(1)	12
Emerging Markets	40	35	14	40	35	—	14	74	66	12	74	66	(2)	15
Diabetes Group	462	450	3	462	450	(1)	3	914	894	2	914	894	(3)	3
U.S.	4,152	4,098	1	4,152	4,098	—	1	8,154	8,240	(1)	8,154	8,240	—	(1)
Non-U.S. Developed	2,209	2,052	8	2,209	2,052	62	5	4,440	4,249	4	4,440	4,249	108	2
Emerging Markets	984	908	8	984	908	(12)	10	1,917	1,843	4	1,917	1,843	(65)	8
TOTAL	\$ 7,345	\$ 7,058	4%	\$ 7,345	\$ 7,058	\$ 50	3%	\$ 14,511	\$ 14,332	1%	\$ 14,511	\$ 14,332	\$ 43	1%

See description of non-GAAP financial measures at the end of the earnings press release.

(1) Fiscal year 2016 was a 53-week year, with the extra week included in the first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates that the extra week impact on first quarter revenue was approximately \$450 million.

(2) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior year periods using average exchange rates in effect during the applicable prior year period.

(3) In fiscal year 2017, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from certain product lines in Restorative Therapies Group to Cardiac & Vascular Group's Aortic & Peripheral Vascular division. As a result, fiscal year 2016 results have been recast to adjust for this realignment.

(4) U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.

MEDTRONIC PLC
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

(in millions, except per share data)	Three months ended		Six months ended	
	October 28, 2016	October 30, 2015	October 28, 2016	October 30, 2015
Net sales	\$ 7,345	\$ 7,058	\$ 14,511	\$ 14,332
Costs and expenses:				
Cost of products sold	2,326	2,182	4,587	4,638
Research and development expense	554	545	1,110	1,103
Selling, general, and administrative expense	2,416	2,343	4,844	4,792
Restructuring charges, net	47	73	141	140
Certain litigation charges	—	26	82	26
Acquisition-related items	28	49	80	120
Amortization of intangible assets	500	483	987	964
Other expense, net	89	57	128	118
Operating profit	1,385	1,300	2,552	2,431
Interest income	(91)	(107)	(184)	(222)
Interest expense	264	324	536	630
Interest expense, net	173	217	352	408
Income from operations before income taxes	1,212	1,083	2,200	2,023
Provision for income taxes	101	563	160	683
Net income	1,111	520	2,040	1,340
Net loss attributable to noncontrolling interests	(4)	—	(4)	—
Net income attributable to Medtronic	\$ 1,115	\$ 520	\$ 2,044	\$ 1,340
Basic earnings per share	\$ 0.81	\$ 0.37	\$ 1.47	\$ 0.95
Diluted earnings per share	\$ 0.80	\$ 0.36	\$ 1.46	\$ 0.94
Basic weighted average shares outstanding	1,380.0	1,412.9	1,386.5	1,415.6
Diluted weighted average shares outstanding	1,392.5	1,428.8	1,400.2	1,432.7
Cash dividends declared per ordinary share	\$ 0.43	\$ 0.38	\$ 0.86	\$ 0.76

MEDTRONIC PLC
NET INCOME AND DILUTED EPS GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)

Three months ended October 28, 2016									
(in millions, except per share data)	Net Sales	Cost of Products Sold	Gross Margin Percent	Operating Profit	Operating Profit Percent	Income from Operations Before Income Taxes	Net Income attributable to Medtronic	Diluted EPS ⁽¹⁾	Effective Tax Rate
GAAP	\$ 7,345	\$ 2,326	68.3%	\$ 1,385	18.9%	\$ 1,212	\$ 1,115	\$ 0.80	8.3%
Non-GAAP Adjustments: (2)									
Impact of inventory step-up (a)	—	(38)		38		38	24	0.02	36.8
Restructuring charges, net	—	—		47		47	35	0.03	25.5
Acquisition-related items	—	—		28		28	2	—	92.9
Amortization of intangible assets	—	—		500		500	385	0.28	23.0
Non-GAAP	\$ 7,345	\$ 2,288	68.8%	\$ 1,998	27.2%	\$ 1,825	\$ 1,561	\$ 1.12	14.7%
Foreign currency impact	(50)	(58)	0.6	108	1.7			0.06	
Constant Currency Adjusted	\$ 7,295	\$ 2,230	69.4%	\$ 2,106	28.9%			\$ 1.18	

Three months ended October 30, 2015									
(in millions, except per share data)	Net Sales	Cost of Products Sold	Gross Margin Percent	Operating Profit	Operating Profit Percent	Income from Operations Before Income Taxes	Net Income attributable to Medtronic	Diluted EPS ⁽¹⁾	Effective Tax Rate
GAAP	\$ 7,058	\$ 2,182	69.1%	\$ 1,300	18.4%	\$ 1,083	\$ 520	\$ 0.36	52.0%
Non-GAAP Adjustments: (2)									
Restructuring charges, net	—	—		73		73	56	0.04	23.3
Certain litigation charges, net	—	—		26		26	17	0.01	34.6
Acquisition-related items	—	—		49		49	32	0.02	34.7
Loss on previously held forward starting interest rate swaps (b)	—	—		—		45	29	0.02	35.6
Amortization of intangible assets	—	—		483		483	373	0.26	22.8
Certain tax adjustments (c)	—	—		—		—	442	0.31	—
Non-GAAP	\$ 7,058	\$ 2,182	69.1%	\$ 1,931	27.4%	\$ 1,759	\$ 1,469	\$ 1.03	16.5%

Year over year percent change:	Net Income	Diluted EPS
GAAP	114%	122%
Non-GAAP	6%	9%
Constant Currency Adjusted Non-GAAP		15%

See description of non-GAAP financial measures at the end of the earnings press release.

- (1) The data in this schedule has been intentionally rounded to the nearest \$0.01 and, therefore, may not sum.
- (2) Non-GAAP adjustments relate to charges or gains that management believes may or may not recur with similar materiality or impact on results in future periods.
 - (a) Represents amortization of step-up in fair value of inventory acquired in connection with the HeartWare acquisition.
 - (b) Relates to losses incurred from the unwinding of forward starting interest rate swaps, which were previously entered into in advance of a planned debt issuance that is no longer expected post the internal reorganization described in footnote (c). The losses were recorded in *interest expense, net* in our condensed consolidated statements of income.
 - (c) Primarily relates to U.S. income tax expense resulting from the Company's completion of an internal reorganization of the ownership of certain legacy Covidien businesses that reduced the cash and investments held by Medtronic's U.S.-controlled non-U.S. subsidiaries.

MEDTRONIC PLC
NET INCOME AND DILUTED EPS GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)

Six months ended October 28, 2016									
(in millions, except per share data)	Net Sales	Cost of Products Sold	Gross Margin Percent	Operating Profit	Operating Profit Percent	Income from Operations Before Taxes	Net Income attributable to Medtronic	Diluted EPS ⁽¹⁾	Effective Tax Rate
GAAP	\$ 14,511	\$ 4,587	68.4%	\$ 2,552	17.6%	\$ 2,200	\$ 2,044	\$ 1.46	7.3%
Non-GAAP Adjustments: (2)									
Impact of inventory step-up (a)	—	(38)		38		38	24	0.02	36.8
Restructuring charges, net	—	(10)		151		151	113	0.08	25.2
Certain litigation charges	—	—		82		82	52	0.04	36.6
Acquisition-related items	—	—		80		80	41	0.03	48.8
Amortization of intangible assets	—	—		987		987	761	0.54	22.9
Certain tax adjustments (b)	—	—		—		—	(31)	(0.02)	—
Non-GAAP	\$ 14,511	\$ 4,539	68.7%	\$ 3,890	26.8%	\$ 3,538	\$ 3,004	\$ 2.15	15.2%
Foreign currency impact	(43)	(77)	0.5	178	1.3			0.10	
Constant Currency Adjusted	\$ 14,468	\$ 4,462	69.2%	\$ 4,068	28.1%			\$ 2.25	

Six months ended October 30, 2015									
(in millions, except per share data)	Net Sales	Cost of Products Sold	Gross Margin Percent	Operating Profit	Operating Profit Percent	Income from Operations Before Taxes	Net Income attributable to Medtronic	Diluted EPS ⁽¹⁾	Effective Tax Rate
GAAP	\$ 14,332	\$ 4,638	67.6%	\$ 2,431	17.0%	\$ 2,023	\$ 1,340	\$ 0.94	33.8%
Non-GAAP Adjustments: (2)									
Impact of inventory step-up (c)	—	(226)		226		226	165	0.12	27.0
Restructuring charges, net	—	—		140		140	108	0.08	22.9
Certain litigation charges	—	—		26		26	17	0.01	34.6
Acquisition-related items	—	—		120		120	84	0.06	30.0
Loss on previously held forward starting interest rate swaps (d)	—	—		—		45	29	0.02	35.6
Amortization of intangible assets	—	—		964		964	746	0.52	22.6
Certain tax adjustments (e)	—	—		—		—	442	0.31	—
Non-GAAP	\$ 14,332	\$ 4,412	69.2%	\$ 3,907	27.3%	\$ 3,544	\$ 2,931	\$ 2.05	17.3%

Year over year percent change:

	Net Income	Diluted EPS
GAAP	53%	55%
Non-GAAP	2%	5%
Constant Currency Adjusted Non-GAAP		10%

See description of non-GAAP financial measures contained in this release.

- (1) The data in this schedule has been intentionally rounded to the nearest \$0.01 and, therefore, may not sum.
- (2) Non-GAAP adjustments relate to charges or gains that management believes may or may not recur with similar materiality or impact on results in future periods.
 - (a) Represents amortization of step-up in fair value of inventory acquired in connection with the HeartWare acquisition.
 - (b) The net benefit in certain tax adjustments relates to the resolution of various tax positions from prior years and other certain tax charges recorded in connection with the redemption of an intercompany minority interest.
 - (c) Represents amortization of step-up in fair value of inventory acquired in connection with the Covidien acquisition.

- (d) Relates to losses incurred from the unwinding of forward starting interest rate swaps, which were previously entered into in advance of a planned debt issuance that is no longer expected post the internal reorganization described in footnote (e). The losses were recorded in *interest expense, net* in our condensed consolidated statements of income.
- (e) Primarily relates to U.S. income tax expense resulting from the Company's completion of an internal reorganization of the ownership of certain legacy Covidien businesses that reduced the cash and investments held by Medtronic's U.S.-controlled non-U.S. subsidiaries.

MEDTRONIC PLC
RECONCILIATION OF OPERATING CASH FLOW TO FREE CASH FLOW
(Unaudited)

(in millions)	Six months ended	Three months ended	Three months ended
	October 28, 2016	October 28, 2016	July 29, 2016
Net cash provided by operating activities	3,022	1,472	1,550
Additions to property, plant, and equipment	(598)	(268)	(330)
Free Cash Flow (1)	<u>\$ 2,424</u>	<u>\$ 1,204</u>	<u>\$ 1,220</u>

See description of non-GAAP financial measures at the end of the earnings press release.

(1) Free cash flow represents operating cash flows less property, plant, and equipment additions.

MEDTRONIC PLC
RECONCILIATION OF ESTIMATED FULL FISCAL YEAR OPERATING CASH FLOW TO FREE CASH FLOW
(Unaudited)

(in billions)	Full Fiscal Year 2017 Estimate	
	Low	High
Net cash provided by operating activities (1)	\$ 6.2	\$ 7.1
Additions to property, plant, and equipment	(1.2)	(1.1)
Free Cash Flow (2)	<u>\$ 5.0</u>	<u>\$ 6.0</u>

See description of non-GAAP financial measures at the end of the earnings press release.

- (1) Estimated full fiscal year net cash provided by operating activities includes assumptions related to the timing and amount of cash flows resulting from charges or gains that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). The estimated full year range is broad to capture the unpredictability inherent in the timing and amount of cash flows related to Non-GAAP Adjustments. The estimate includes projected cash flows related to Non-GAAP Adjustments which have been recognized in the Company's statements of income. If the Company were to incur charges or gains related to Non-GAAP Adjustments which have not yet been recognized in the statements of income, the estimated full fiscal year net cash provided by operating activities may be significantly effected.
- (2) Free cash flow represents operating cash flows less property, plant, and equipment additions.

MEDTRONIC PLC
 SECOND QUARTER SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE (SG&A), RESEARCH AND
 DEVELOPMENT EXPENSE (R&D), AND OTHER (INCOME) EXPENSE, NET ON AN ADJUSTED BASIS
 (Unaudited)

Three months ended October 28, 2016

(in millions)	Net Sales	SG&A Expense	SG&A Expense as a Percentage of Net Sales	R&D Expense	R&D Expense as a Percentage of Net Sales	Other (Income) Expense, net	Other (Income) Expense, net as a Percentage of Net Sales
As reported	\$ 7,345	\$ 2,416	32.9%	\$ 554	7.5%	\$ 89	1.2 %
Foreign currency impact	(50)	(10)		—		(90)	
Adjusted	\$ 7,295	\$ 2,406	33.0%	\$ 554	7.6%	\$ (1)	— %

See description of non-GAAP financial measures at the end of the earnings press release.

MEDTRONIC PLC
PAIN THERAPIES REVENUE GROWTH ON AN ADJUSTED BASIS
FOR THE THREE MONTHS ENDED OCTOBER 28, 2016
(Unaudited)

	Constant Currency Growth⁽¹⁾
Pain Therapies	(2)%
Drug business	3
Adjusted Pain Therapies	1 %

See description of non-GAAP financial measures at the end of the earnings press release.

(1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior year periods using average exchange rates in effect during the applicable prior year period.

MEDTRONIC PLC
CONSOLIDATED BALANCE SHEETS
(Unaudited)

(in millions)	October 28, 2016	April 29, 2016
<u>ASSETS</u>		
Current assets:		
Cash and cash equivalents	\$ 2,954	\$ 2,876
Investments	8,303	9,758
Accounts receivable, less allowances of \$162 and \$161, respectively	5,661	5,562
Inventories	3,717	3,473
Other current assets	1,891	1,931
Total current assets	22,526	23,600
Property, plant, and equipment, net	4,891	4,841
Goodwill	41,707	41,500
Other intangible assets, net	26,739	26,899
Tax assets	1,250	1,383
Other assets	1,293	1,421
Total assets	\$ 98,406	\$ 99,644
<u>LIABILITIES AND SHAREHOLDERS' EQUITY</u>		
Current liabilities:		
Current debt obligations	\$ 3,367	\$ 993
Accounts payable	1,659	1,709
Accrued compensation	1,477	1,712
Other accrued expenses	3,098	2,751
Total current liabilities	9,601	7,165
Long-term debt	29,010	30,109
Accrued compensation and retirement benefits	1,768	1,759
Accrued income taxes	2,381	2,903
Deferred tax liabilities	3,754	3,729
Other liabilities	1,599	1,916
Total liabilities	48,113	47,581
Commitments and contingencies		
Shareholders' equity:		
Ordinary shares — par value \$0.0001	—	—
Retained earnings	52,514	53,931
Accumulated other comprehensive loss	(2,328)	(1,868)
Total shareholders' equity	50,186	52,063
Noncontrolling interests	\$ 107	\$ —
Total equity	\$ 50,293	\$ 52,063
Total liabilities and equity	\$ 98,406	\$ 99,644

MEDTRONIC PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

(in millions)	Six months ended	
	October 28, 2016	October 30, 2015
Operating Activities:		
Net income	\$ 2,040	\$ 1,340
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	1,469	1,397
Amortization of debt discount and issuance costs	14	15
Acquisition-related items	(47)	222
Provision for doubtful accounts	18	30
Deferred income taxes	(50)	(274)
Stock-based compensation	190	209
Other, net	(105)	(85)
Change in operating assets and liabilities, net of acquisitions:		
Accounts receivable, net	(89)	(1)
Inventories	(187)	(326)
Accounts payable and accrued liabilities	(271)	(369)
Other operating assets and liabilities	75	73
Certain litigation charges	82	26
Certain litigation payments	(117)	(162)
Net cash provided by operating activities	3,022	2,095
Investing Activities:		
Acquisitions, net of cash acquired	(1,306)	(997)
Additions to property, plant, and equipment	(598)	(446)
Purchases of investments	(2,110)	(3,370)
Sales and maturities of investments	3,625	2,752
Other investing activities, net	32	(13)
Net cash used in investing activities	(357)	(2,074)
Financing Activities:		
Acquisition-related contingent consideration	(36)	(19)
Change in current debt obligations, net	1,154	1,277
Proceeds from short-term borrowings (maturities greater than 90 days)	4	48
Issuance of long-term debt	131	—
Payments on long-term debt	(252)	(1,608)
Dividends to shareholders	(1,192)	(1,075)
Issuance of ordinary shares	260	263
Repurchase of ordinary shares	(2,794)	(1,460)
Other financing activities	74	49
Net cash used in financing activities	(2,651)	(2,525)
Effect of exchange rate changes on cash and cash equivalents	64	39
Net change in cash and cash equivalents	78	(2,465)
Cash and cash equivalents at beginning of period	2,876	4,843
Cash and cash equivalents at end of period	\$ 2,954	\$ 2,378
Supplemental Cash Flow Information		
Cash paid for:		
Income taxes	\$ 258	\$ 1,021
Interest	559	652